RXST - RxSight, Inc.
RxSight (NASDAQ: RXST - Get Free Report) and Bioventus (NASDAQ: BVS - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability. Analyst Ratings This is a summary of recent recommendations
RxSight (NASDAQ: RXST - Get Free Report) and Organigram Global (NASDAQ: OGI - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability. Earnings and Valuation This table compares RxSight and
Cerus (NASDAQ: CERS - Get Free Report) and RxSight (NASDAQ: RXST - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings. Analyst Ratings This is a breakdown of recent ratings
Corient Private Wealth LP bought a new stake in shares of RxSight, Inc. (NASDAQ: RXST) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 85,838 shares of the company's stock, valued at approximately $414,000. Corient Private Wealth LP owned 0.21% of RxSight at the
BlackRock Inc. acquired a new stake in RxSight, Inc. (NASDAQ: RXST) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,790,408 shares of the company's stock, valued at approximately $27,910,000. BlackRock Inc. owned 13.99% of RxSight at the end
ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation will be available on the Company's investor relations website at https://investors.rxsight.com/.
RxSight (NASDAQ: RXST - Get Free Report) and Futureworld (OTCMKTS:FWDG - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk. Risk and Volatility RxSight has a beta of 1.13, suggesting
RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
RxSight NASDAQ: RXST reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026 financial guidance as new Chief Executive Officer Aziz Mottiwala conducts a broader assessment of the business.
RxSight (NASDAQ: RXST) reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026 financial guidance as new Chief Executive Officer Aziz Mottiwala conducts a broader assessment of the business. Excluding the Alcon-related revenue, product sales were $27.2 million, down 19% from the prior-year period.
RxSight, Inc. (RXST) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.08 per share a year ago.
ALISO VIEJO, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financial outlook.
RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALISO VIEJO, Calif., July 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on July 24, 2026, RxSight granted inducement stock options to purchase a total of 571,286 shares of RxSight's common stock and inducement restricted stock units (RSUs) covering a total of 2,312,138 shares of RxSight's common stock to Aziz Mottiwala, RxSight's new President and Chief Executive Officer in connection with his commencement of employment with RxSight.
ALISO VIEJO, Calif. , July 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on July 24, 2026, RxSight granted inducement stock options to purchase a total of 571,286 shares of RxSight's common stock and inducement restricted stock units (RSUs) covering a total of 2,312,138 shares of RxSight's common stock to Aziz Mottiwala, RxSight's new President and Chief Executive Officer in connection with his commencement of employment with RxSight.
RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ALISO VIEJO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced a planned leadership transition effective July 20, 2026, with Aziz Mottiwala appointed President and Chief Executive Officer, succeeding Ron Kurtz, M.D., who will continue to serve as Chief Medical Officer.
ALC is developing adjustable presbyopia-correcting lenses that pair advanced optics with post-surgery light adjustment.
RxSight NASDAQ: RXST reported preliminary second-quarter financial results and provided updates on its product pipeline following a newly announced strategic collaboration agreement with Alcon, with management pointing to both near-term commercial headwinds and longer-term opportunities in adjustable intraocular lenses.
RxSight, Inc. exhibits quantitative similarities to other small caps that I have rated here on Seeking Alpha that strongly outperformed the market. RXST is an 'NCAV' opportunity, a company that sells for less than its current asset value even though management is putting the company back on the growth track. My thesis is grounded in historical patterns where cash-rich, loss-making small caps often resolve operational issues before exhausting reserves.